Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 3/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL23211912 | 0.90 | OPRD1 (0.54) | OPRD1DPP4DPP7DPP9SLC6A3 | |
| SCHEMBL21382071 | 0.88 | ACHE (0.43) | OPRD1SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL29734367 | 0.88 | ACHE (0.43) | OPRD1SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL21382069 | 0.88 | ACHE (0.43) | OPRD1SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL21382142 | 0.88 | ACHE (0.43) | OPRD1SLC6A3SLC6A2SLC6A4 | |
| Oxalic Acid SCHEMBL7329503 | 0.83 | OPRD1 (0.51) | OPRD1SLC6A3SLC6A2SLC6A4 | |
| Trifluoroacetic Acid SCHEMBL17460197 | 0.82 | OPRD1 (0.56) | OPRD1DPP4DPP7SLC6A2SLC6A4 | |
| Trifluoroacetic Acid SCHEMBL21381685 | 0.81 | OPRD1 (0.44) | OPRD1KMT2A | |
| Trifluoroacetic Acid SCHEMBL30567963 | 0.81 | OPRD1 (0.44) | OPRD1KMT2A | |
| SCHEMBL7319671 | 0.80 | SLC6A2 (0.45) | OPRD1SLC6A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-3768684-B1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN LA ROCHE (CH) | 2023-02-22 | — | — | EP | disclosed |
| US-20210107920-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2021-04-15 | — | — | US | disclosed |
| EP-3768684-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2021-01-27 | — | — | EP | disclosed |
| WO-2019180185-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107920-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, LPL, LIPC | OPRD1 2016/4885DPP4 542/4885DPP7 730/4885 |
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, LPL, LIPC | OPRD1 2016/4885DPP4 542/4885DPP7 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.